References
- CappuccioFPMarkanduNDSagnellaGAMacGregorGASodium restriction lowers high blood pressure through a decreased response of the renin system – direct evidence using saralasinJ Hypertens1985332432473894515
- MacGregorGAMarkanduNDSingerDRCappuccioFPShoreACSagnellaGAModerate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind studyBr Med J198729465715315343103761
- MacGregorGAMarkanduNDSagnellaGASingerDRCappuccioFPDouble-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertensionLancet198928674124412472573761
- SingerDRMarkanduNDCappuccioFPMillerMASagnellaGAMacGregorGAReduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazideHypertension1995255104210447737713
- FrommMFDarbarDDell’OrtoSRodenDMModulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loadingJ Pharmacol Exp Ther1999290125325810381784
- DarbarDFrommMFDell’OrtoSModulation by dietary salt of verapamil disposition in humansCirculation19989824270227089851956
- DarbarDDell’OrtoSMorikeKWilkinsonGRRodenDMDietary salt increases first-pass elimination of oral quinidineClin Pharmacol Ther19976132923009084454
- KosugeKChuangAIUematsuSDiscovery of osmosensitive transcriptional regulation of human cytochrome P450 3As by the tonicity-responsive enhancer binding protein (nuclear factor of activated T cells 5)Mol Pharmacol200772482683717600221
- KangHJSongISLeeSSYooMAShinJGEffects of dietary salt on the expression of drug transporters, cytochrome P4503a, and nuclear receptors in ratsXenobiotica200838214715518197556
- AziziMBlanchardACharbitBEffect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockersHypertension20136161239124523608658
- CharytanDMFormanJPYou are what you eat: dietary salt intake and renin-angiotensin blockade in diabetic nephropathyKidney Int201282325725922791321
- KimJWYiSKimTEIncreased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicinJ Clin Pharmacol2013531758123400746
- World Medical Association Declaration of HelsinkiEthical Principles for Medical Research Involving Human Subjects, 55th WMA General AssemblyTokyo2004 Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdfAccessed April 4, 2015
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6 (R1). Step 4 version, ICH Harmonised Tripartite Guideline1996 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdfAccessed April 2015
- BonatePLHowardDPharmacokinetics in Drug Development. Volume 1: Clinical Study Design and AnalysisArlington, VAAmerican Association of Pharmaceutical Scientists2004
- MidhaKKRawsonMJHubbardJWThe bioequivalence of highly variable drugs and drug productsInt J Clin Pharmacol Ther2005431048549816240706
- Food and Drug AdministrationGuidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs – General ConsiderationsRockville, MDFood and Drug Administration2014
- YiSKimTEYoonSHPharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteersJ Cardiovasc Pharm2011576682689
- ChiYHLeeHPaikSHSafety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjectsAm J Cardiovasc Drugs201111533534621910510
- AtlasSAThe renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibitionJ Manag Care Pharm2007138 Suppl B92017970613